Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
|
February 6, 2016
[The significance of biobanks for clinical development]
Marlene Thomas, Astrid Kiermaier, Michael Cannarile
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 15, 2015
Reply to a. Avan et Al
José Baselga, Emma Clark, Astrid Kiermaier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 22, 2014
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer
José Baselga, Javier Cortés, Seock-Ah Im, et al.
JCO Clinical Cancer Informatics
|
November 3, 2023
Correlation Between Early Trends of a Prognostic Biomarker and Overall Survival in Non-Small-Cell Lung Cancer Clinical Trials
Hugo Loureiro, Theresa M Kolben, Astrid Kiermaier, et al.
Breast Cancer Research : BCR
|
July 10, 2014
Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study
Andreas Schneeweiss, Stephen Chia, Roberto Hegg, et al.
The Lancet. Oncology
|
December 15, 2016
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study
Stephen J Luen, Roberto Salgado, Stephen Fox, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
September 6, 2022
Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial
Josep Tabernero, Paulo M Hoff, Lin Shen, et al.
Journal of the National Cancer Institute
|
April 4, 2026
The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial
Elisa Agostinetto, Gabriella Gentile, Faye Samy, et al.
Breast Cancer Research : BCR
|
February 11, 2017
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Giampaolo Bianchini, Astrid Kiermaier, Giulia Valeria Bianchi, et al.
Journal of the National Cancer Institute
|
May 23, 2018
Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy
Michail Ignatiadis, Gert Van den Eynden, Salgado Roberto, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
|
February 6, 2016
[The significance of biobanks for clinical development]
Marlene Thomas, Astrid Kiermaier, Michael Cannarile
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 15, 2015
Reply to a. Avan et Al
José Baselga, Emma Clark, Astrid Kiermaier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 22, 2014
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer
José Baselga, Javier Cortés, Seock-Ah Im, et al.
JCO Clinical Cancer Informatics
|
November 3, 2023
Correlation Between Early Trends of a Prognostic Biomarker and Overall Survival in Non-Small-Cell Lung Cancer Clinical Trials
Hugo Loureiro, Theresa M Kolben, Astrid Kiermaier, et al.
Breast Cancer Research : BCR
|
July 10, 2014
Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study
Andreas Schneeweiss, Stephen Chia, Roberto Hegg, et al.
The Lancet. Oncology
|
December 15, 2016
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study
Stephen J Luen, Roberto Salgado, Stephen Fox, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
September 6, 2022
Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial
Josep Tabernero, Paulo M Hoff, Lin Shen, et al.
Journal of the National Cancer Institute
|
April 4, 2026
The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial
Elisa Agostinetto, Gabriella Gentile, Faye Samy, et al.
Breast Cancer Research : BCR
|
February 11, 2017
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Giampaolo Bianchini, Astrid Kiermaier, Giulia Valeria Bianchi, et al.
Journal of the National Cancer Institute
|
May 23, 2018
Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy
Michail Ignatiadis, Gert Van den Eynden, Salgado Roberto, et al.
Page
of 2